Study of OMS906 for C3G and ICGN kidney diseases
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a kidney biopsy diagnosis of C3G or ICGN (within the last 3 years).
- You have had high protein in your urine (at least 0.8 grams per gram of creatinine) in two separate tests, 2 to 4 weeks apart.
- Your kidney function (eGFR) is at least 45 mL/min, and you are on a stable dose of blood pressure medicine (ACE inhibitor or ARB) for at least 3 months.
- Your blood C3 complement level is lower than normal.
- You must be up-to-date on certain vaccines (meningococcal, pneumococcal, and Hib) or willing to get them before starting the study drug.
- You and your partner (if applicable) must use highly effective birth control for 20 weeks after the last dose of study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NM8074 for adults with C3 glomerulopathy, a kidney disease. The medicine may help reduce kidney damage. Participants will receive the study drug and be monitored for safety and effectiveness.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
This study follows people in Russia with C3 glomerulopathy or IC-MPGN to understand how these kidney diseases progress over time. It does not test a new treatment, but gathers information from medical records and check-ups to learn more about the conditions.
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.